News
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback